OncoPrecision

Please join us in congratulating our recently promoted Onconauts! ????

Our CEO, Tarek Ali Zaki, shared our story at yesterday's Industry Insights on Research and Innovation Seminar at NYU Langone hosted by NYU Technology Opportunities & Ventures. Thank you for having us!

On this #WorldCancerDay we stand united with patients, their families, and all lives that are touched by cancer, as we strive to advance much-needed transformative therapies. We join the Union for International Cancer Control (UICC)'s new three-year #UnitedByUnique campaign to raise awareness about cancer, encourage its prevention, and remind ourselves that behind every patient lies a unique human story ??

We are super excited to host these amazing panelists at our Jan 15th JPM mixer, co-hosted by SOSV’s IndieBio, LOTTE Ventures U.S. and GQR. Looking forward to an engaging session with Jonathan Kotula, Tarek Ali Zaki, Khatija A., Chris Mason, Isaac Kang and Pavel Printsev! We will be exploring capital-efficient pathways into the clinic, leveraging geographic advantages for development, and finding smart ways to arbitrage geography for in- and out-licensing opportunities. For founders and investors interested in leading and funding clinical transitions, the guest list is filling rapidly and space is limited - don’t forget to register today! https://lu.ma/ew7dbw2n

Happy Holidays from the OncoPrecision Team!

Our CEO, Tarek Ali Zaki, will be participating in a panel discussion on Leveraging the Global Landscape: New Pathways and Geographies in Drug Development on January 15th hosted by SOSV's IndieBio and LOTTE Ventures U.S. More information on the event and link to register: https://lu.ma/ew7dbw2n We'll be in town the week of January 13th during J.P. Morgan's 43rd Annual Healthcare Conference, so please reach out if you'd like to learn more about our platform, pipeline, and explore potential collaborations.

Our Team attended the 66th American Society of Hematology Annual Meeting & Exposition in San Diego, our company’s third year doing so. It was a great opportunity to learn about the latest innovations in the field, meet with our clinical and pharmaceutical partners, and connect with fellow researchers seeking to move the needle for patients. Some of this year’s highlights pictured: catching up with our dear Advisors (Dr. Gwen Nichols, Chief Medical Officer of The Leukemia & Lymphoma Society at their stand and Dr. Jorge Solimano, VP and Head of Hematology of CEMIC over lunch), our annual picture with the ASH sign, and a bit of fun. We leave the conference feeling inspired and driven to accelerate our research for the benefit of patients.

We’re thrilled to welcome Dr. Stefan Oschmann to our Advisory Board. Dr. Oschmann served as Chairman & CEO of Merck KGaA from 2016 to 2021, successfully leading the company through a period of transformation and growth. During his tenure, Merck developed and launched two blockbuster products in oncology and neuroscience. Prior to leading Merck, Dr. Oschmann held numerous leadership roles at the company, including President & CEO Merck Biopharma, CEO Healthcare, and as a Member of the Executive Board. Following his retirement from Merck KGaA, he served as chairman of UCB and is currently Chairman of AiCuris, as well as a Partner at European private equity firm Armira. Dr. Oschmann holds a PhD from the Ludwig Maximilian University of Munich.?

Last Thursday, our Team participated in The Leukemia & Lymphoma Society's Light the Night event in Manhattan's South Street Seaport for the third year in a row to raise funds and awareness for blood cancer patients. It was a powerful reminder of the importance of our work as we walked to bring light to the darkness of cancer alongside an inspiring community of patients, survivors, and their loved ones ????

Our Team wore pink for the #InternationalDayAgainstBreastCancer to raise awareness about breast cancer and promote early detection, diagnosis, and treatment ????